May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Celecoxib, a selective COX–2 inhibitor, inhibits diabetes–induced retinal PGE2 secretion
Author Affiliations & Notes
  • R.N. Aravalli
    Pharmaceutical Sciences,
    University of Nebraska Medical Center, Omaha, NE
  • S.P. Ayalasomayajula
    Pharmaceutical Sciences,
    University of Nebraska Medical Center, Omaha, NE
  • A.C. Amrite
    Pharmaceutical Sciences,
    University of Nebraska Medical Center, Omaha, NE
  • U.B. Kompella
    Pharmaceutical Sciences,
    Ophthalmology,
    University of Nebraska Medical Center, Omaha, NE
  • Footnotes
    Commercial Relationships  R.N. Aravalli, None; S.P. Ayalasomayajula, None; A.C. Amrite, None; U.B. Kompella, None.
  • Footnotes
    Support  NIH Grant DK064172
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 3580. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R.N. Aravalli, S.P. Ayalasomayajula, A.C. Amrite, U.B. Kompella; Celecoxib, a selective COX–2 inhibitor, inhibits diabetes–induced retinal PGE2 secretion . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3580.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Previously we have demonstrated that celecoxib, a selective inhibitor of cyclooxygenase–2 (COX–2) enzyme, inhibits diabetes–induced retinal vascular endothelial growth factor (VEGF) expression and vascular leakage. The objective of this study was to determine whether COX–2 is responsible for diabetes–induced PGE2 secretion from isolated rat retinas. Methods: All the animals were treated according to the ARVO statement for animal care. Diabetes was induced in Sprague Dawley rats by single intraperitoneal injection of streptozotocin (60 mg/kg) following 24 hours of fasting. The blood glucose levels were determined using onetouch ultra® and animals with blood glucose levels > 250 mg/dL were deemed diabetic. On day 14, the animals were euthanized with single intraperitoneal injection of pentobarbital sodium (250 mg/Kg). The retinas (both nondiabetic and diabetic rats) were isolated and immersed in 100 µL of assay buffer (pH: 7.4) and incubated in the presence or absence of 1 µM celecoxib (a selective COX–2 inhibitor) or SC560 (a selective COX–1 inhibitor). The secreted PGE2 levels at the end of 2 hours in the supernatants were determined using EIA (Cayman chemicals). Results: The secreted PGE2 levels from isolated diabetic retinas were significantly higher compared to nondiabetic controls (32.1 ± 4.7 vs 11.1 ± 1.6 pg/mg, p<0.05). Co–incubation with celecoxib (11.76 ± 4.5 pg/mg, p<0.05) but not SC560 (30 ± 1.2 pg/mg) significantly reduced diabetes–induced retinal PGE2 secretion. However, both celecoxib and SC560 had no affect on basal PGE2 secretion from the isolated non–diabetic rat retinas Conclusion: The PGE2 secretion is significantly induced in diabetic rat retinas. Celecoxib but not SC560 inhibited diabetes–induced PGE2 secretion from isolated retinas, suggesting that the activity of COX–2 but not COX–1 might be responsible for the diabetes induced PGE2 secretion. Financial Support: Supported by NIH grant DK064172. Disclosures/Conflicts: None

Keywords: retina • diabetes • diabetic retinopathy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×